Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Apr 22, 2024 10:42pm
166 Views
Post# 36002567

RE:Bloom Burton Conference

RE:Bloom Burton ConferenceThanks Bball.  I thought the Q&A showed a high level of engagement and curiosity from the audience.  The questions were very specific, indicating that the audience had been doing their research in advance of the brief.  

Mr. Warma does need to know that it is okay to not know the answer to detailed questions in a forum like this.  He'll learn.  I think he is doing a great job so far.  Good times ahead perhaps.

I'm hoping to get to 10K shares before the next move up.  Not sure when that will be.  Maybe Phase1a data, but I don't think that will tell us all that much.  6 months into Ph1b sure might be a good time to swing for the fences.  But the ARIA-E data will also be a key milestone.  I'm not sure if 6 months is long enough for that to be definitive, but any clinical data supporting the hypothesis will be truly exciting.
<< Previous
Bullboard Posts
Next >>